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FSGS forms are deﬁned based on the underlying cause, theglomerulosclerosis
Una  causa  poco  frecuente  de  diarre
glomeruloesclerosis  focal  y  segme
Dear Editor,
Focal segmental glomerulosclerosis (FSGS) symbolizes a com-
mon histologic pattern of glomerular injury associated with
numerous disease mechanisms. Ulcerative colitis (UC) repre-
sents one of the types of inﬂammatory bowel disease, which
occurs in genetically predisposed individuals. The coexistence
of these two diseases is an unexpected condition. Lately,
case reports have been published documenting the devel-
opment of nephropathy after treatment of ulcerative colitis
with mesalamine or sulphasalazine. In cases in the literature,
this coexistence has been identiﬁed as associated with 5-ASA
therapy.1–5 In this case, we report the ulcerative colitis occur-
ring in a patient with focal segmental glomerulosclerosis not
afﬁliated with 5-ASA therapy.
A 66-year-old man, with a 3-year history of focal segmen-
tal glomerulosclerosis, was admitted with bloody and mucoid
diarrhea which had been for lasting for 10 days. There was
no fever, nausea, vomiting or infection. There was no feature
in the patient’s history except diarrhea. Physical examina-
tion also was normal. Laboratory investigation demonstrated
impaired renal function and proteinuria due to focal segmen-
tal glomerulosclerosis. Renal function test which is similar to
the old values showed serum creatinine level of 3.15 mg/dl
(0.8–1.3), BUN level of 89 mg/dl (17–43) and 24-h urine pro-
tein level of 1876 mg/day (<200). In addition, his erythrocyte
sedimentation rate (ESR) was 79 mm/h  (<20) and C-reactive
protein (CRP) was 6.66 mg/dl (<0.4). A large amount of leuko-
cytes and erythrocytes was seen in the stool microscopy. Stool
cultures were detected negative twice. Colonoscopy revealed
that there were to exudates of millimetric ulcers descending
colon, sigmoid colon and rectum. The colon biopsy conﬁrmed
the diagnosis of ulcerative colitis.en  pacientes  con
ria
The patient was started on mesalamine. His symptoms
showed marked improvements after starting mesalamine
treatment. After treatment, laboratory investigation demon-
strated; creatinine level of 3.7 mg/dl (0.8–1.3), BUN level of
116 mg/dl (17–43), ESR level of 38 mm/h  (<20), CRP level of
0.319 mg/dl (<0.4), and 24-h urine protein level of 2099 mg/day
(<200). There were no abnormalities suggestive of nephro-
toxicity in patients due to mesalamine, while acute phase
reactants declined. The decline in ESR and CRP levels is
thought to be in favor of improving ulcerative colitis activation.
A focal segmental glomerulosclerosis after ulcerative col-
itis treatment with mesalamine and sulfasalazine has been
reported in the literature.1 Additionally in the literature,
there have been several minimal changes in the disease fol-
lowing the treatment of inﬂammatory bowel disease with
mesalamine or sulfasalazine.2–6 A case report has been pub-
lished of nephrotic syndrome due to Crohn’s disease with
mesalamine treatment.7
In this case, we discuss about the developed ulcerative
colitis in a patient who was followed for focal segmen-
tal glomerulosclerosis. Unlike previously reported cases,
mesalamine and sulfasalazine have no effect on the togeth-
erness of the two diseases. Although primary and secondarypodocyte damage is a common result eventually. Some genetic
factors affect the inﬂammation which is the main cause of
development of the ulcerative colitis. An unknown cause such
as genetic, environmental or infections except drugs may be
factors in the etiology of these two diseases. Furthermore, an
unknown cause can facilitate the development of nephrotox-
icity after mesalamine and/or sulfasalazine treatment. In our
case, the patient’s renal function did not change signiﬁcantly
after mesalamine treatment.
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The coexistence of ulcerative colitis and focal segmen-
tal glomerulosclerosis is a rare condition. Mesalamine and/or
sulfasalazine which have been used in ulcerative colitis treat-
ment may be nephrotoxic. In our case, we have detected
togetherness between ulcerative colitis and non-drug-induced
focal segmental glomerulosclerosis. It should be kept in mind
that the two diseases may be caused by an unknown factor
such as genetic, environmental or infections except drugs.
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ncute  renal  failure  secondary  
nd Fanconi  syndrome  due to 
racaso  renal  agudo  por  nefritis  in
anconi  en  relación  con  metamizo
o the Editor:
e  present a case of acute interstitial nephropathy (AIN) asso-
iated with Fanconi syndrome, resolving after early treatment
ith steroids.
A 49-year-old man  with a past medical history of alco-
olic pancreatitis and liver disease, hypertriglyceridemia, and
ypertension (HTN) treated with gemﬁbrozil and valsartan for
ver one year.
Two months ago, he had undergone an umbilical hernia
epair. At that time, plasma creatinine was 0.79 mg/dl and uri-
alysis was normal. He received a cephalosporin, and 3 weeks
f analgesia in the form of metamizole and paracetamol, with
omplete recovery. Two weeks later, metamizole was restarted
t a dose of 575 mg/8 h orally for ﬂu-like symptoms. He devel-
ped progressive weakness, abdominal pain, and nausea.
ral intake was reduced and BP control worsened, therefore Please cite this article as: Martín-Navarro JA, Petkov-Stoyanov V, G
efritis  intersticial aguda con síndrome de Fanconi en relación con meinterstitial  acute  nephritis
etamizole  and  gemﬁbrozil
sticial  aguda  con  síndrome  de
 gemﬁbrozilo
the doses of valsartan and metamizole were increased, with
additional paracetamol as required. His general condition
worsened, therefore he attended the emergency department
where BP was 135/85. Skin and mucous membranes were dry,
he was afebrile, with no skin lesions, and no other physical
ﬁndings. He had a high urine output (3.5 L/day), which was
macroscopically normal. Blood tests showed a full blood count
with no eosinophilia, metabolic acidosis with normal lactic
acid, normal CK, reduced glomerular ﬁltration rate (GFR),
hypouricemia, and a mixed proteinuria of 1.4 g/24 h. Urinaly-
sis revealed an alkaline pH, glycosuria with normoglycaemia,
microhaematuria, isosthenuria, and the presence of granular
hyaline casts.4,5 There was reduced tubular reabsorption of
phosphate, potassium, calcium, and uric acid, and gener-
alised hyperaminoaciduria. Abdominal ultrasound showed
kidneys measuring 146 mm with preserved corticomedullary
differentiation and no signs of hydronephrosis. There were
no abnormalities of the bladder or prostate. Viral serology and
tumour markers were negative. Immunology was normal,utiérrez-Sánchez MJ, Pedraza-Cezón L. Fracaso renal agudo por
tamizol y gemﬁbrozilo. Nefrologia. 2016;36:321–323.
